Deutsche Bank set a €96.00 ($111.63) price target on Merck KGaA (FRA:MRK) in a research report report published on Thursday morning, Borsen Zeitung reports. The brokerage currently has a neutral rating on the healthcare company’s stock.
Several other research analysts have also weighed in on the company. Nord/LB set a €80.00 ($93.02) target price on Merck KGaA and gave the stock a sell rating in a research report on Thursday, January 24th. HSBC set a €96.00 ($111.63) target price on Merck KGaA and gave the stock a neutral rating in a research report on Monday, March 11th. Sanford C. Bernstein set a €105.00 ($122.09) target price on Merck KGaA and gave the stock a buy rating in a research report on Thursday, March 7th. Goldman Sachs Group set a €95.00 ($110.47) target price on Merck KGaA and gave the stock a neutral rating in a research report on Tuesday, February 12th. Finally, JPMorgan Chase & Co. set a €100.00 ($116.28) target price on Merck KGaA and gave the stock a neutral rating in a research report on Monday, February 18th. One analyst has rated the stock with a sell rating, fifteen have issued a hold rating and five have given a buy rating to the stock. The stock currently has a consensus rating of Hold and a consensus target price of €101.35 ($117.85).
MRK stock traded down €0.04 ($0.05) during mid-day trading on Thursday, hitting €91.62 ($106.53). The stock had a trading volume of 497,029 shares. Merck KGaA has a 1-year low of €76.60 ($89.07) and a 1-year high of €115.00 ($133.72).
MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It offers prescription medicines to treat cancer, multiple sclerosis, infertility, growth deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, as well as squamous cell carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.
Featured Article: How are institutional investors different from individual investors?
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.